Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893315 | 0.79 | KDM1A (0.32) | S1PR5MRGPRX4KDM1APTGER1 | |
| SCHEMBL27745080 | 0.78 | S1PR5 (0.35) | FFAR1S1PR5MRGPRX4KDM1A | |
| SCHEMBL2896992 | 0.78 | PTPN1 (0.43) | MAPK14FFAR1S1PR5MRGPRX4CTSV | |
| SCHEMBL2897148 | 0.76 | CYP19A1 (0.34) | — | |
| SCHEMBL629810 | 0.72 | CHRNA7 (0.39) | FFAR1CHRNA7 | |
| SCHEMBL22412197 | 0.69 | CHRNA7 (0.30) | CHRNA7 | |
| SCHEMBL22412245 | 0.69 | CHRNA7 (0.30) | CHRNA7 | |
| SCHEMBL22442026 | 0.69 | CHRNA7 (0.30) | CHRNA7 | |
| SCHEMBL630191 | 0.69 | CHRNA7 (0.36) | CHRNA7 | |
| SCHEMBL647698 | 0.68 | CHRNA7 (0.34) | MAPK14CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | MAPK14 1091/4885FFAR1 201/4885S1PR5 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.